Laboratory for Neuroregeneration, Netherlands Institute for Neuroscience, Royal Academy of Arts and Sciences, Amsterdam, The Netherlands.
Curr Gene Ther. 2011 Apr;11(2):75-89. doi: 10.2174/156652311794940764.
Peripheral nerve injury in humans often leads to incomplete functional recovery. In this review we discuss the potential for gene therapy to be used as a strategy alongside surgical repair techniques for the study of peripheral nerve regeneration in rodent models and with a view to its eventual use for the promotion of successful regeneration in the clinic. Gene therapy vectors based on herpes simplex virus, adenovirus, lentivirus and adeno-associated virus have been developed to deliver genes to the neurons of the peripheral nervous system, i.e. primary sensory neurons in the dorsal root ganglia and primary motor neurons. Adenoviral and lentiviral vectors have also been used to transduce Schwann cells and fibroblasts in the injured nerve. We present an overview of these vectors, their application so far in the peripheral nervous system, their potential as vectors for enhancing peripheral nerve repair, and the successful interventions that have been demonstrated in animal models. We also discuss some of the limitations of current vectors and how they may be overcome. While the technology for gene delivery is approaching a state of readiness for clinical translation, the current range of therapeutic genes for the repair of the traumatically injured peripheral nerve is mostly limited to neurotrophic factors delivered to neurons, Schwann cells or possibly the target organs. Finally, therefore, we consider what type of therapeutic transgene may be desirable to enhance nerve regeneration in the future.
人类周围神经损伤常导致功能不完全恢复。在这篇综述中,我们讨论了基因治疗作为一种策略与手术修复技术结合使用的可能性,用于研究啮齿动物模型中的周围神经再生,并期望最终在临床上促进成功的再生。基于单纯疱疹病毒、腺病毒、慢病毒和腺相关病毒的基因治疗载体已被开发用于将基因递送至周围神经系统的神经元,即背根神经节中的初级感觉神经元和初级运动神经元。腺病毒和慢病毒载体也已被用于转导损伤神经中的雪旺细胞和成纤维细胞。我们介绍了这些载体,它们迄今为止在周围神经系统中的应用,它们作为增强周围神经修复的载体的潜力,以及在动物模型中已证明的成功干预措施。我们还讨论了当前载体的一些局限性以及如何克服这些局限性。虽然基因传递技术已接近临床转化的准备状态,但目前用于修复创伤性周围神经损伤的治疗性基因大多仅限于递送至神经元、雪旺细胞或可能的靶器官的神经营养因子。因此,最后,我们考虑将来增强神经再生可能需要哪种类型的治疗性转基因。